Attached files
file | filename |
---|---|
10-K - PVCT 10-K 12-31-09 - PROVECTUS BIOPHARMACEUTICALS, INC. | pvct10k123109.htm |
EX-23.1 - PVCT 10-K EX 23.1 12-31-09 - PROVECTUS BIOPHARMACEUTICALS, INC. | pvct10kex23_1.htm |
EX-31.2 - PVCT 10-K EX 31.2 12-31-09 - PROVECTUS BIOPHARMACEUTICALS, INC. | pvct10kex31_2.htm |
EX-32.1 - PVCT 10-K EX 32.1 12-31-09 - PROVECTUS BIOPHARMACEUTICALS, INC. | pvct10kex32_1.htm |
EX-21.1 - PVCT 10-K EX 21.1 12-31-09 - PROVECTUS BIOPHARMACEUTICALS, INC. | pvct10kex21_1.htm |
Exhibit
31.1
Provectus
Pharmaceuticals, Inc.
Certification
Pursuant to Rule 13a-14(a)
Section
302 Certification
I, H. Craig Dees, Ph.D., the Chief Executive Officer of Provectus
Pharmaceuticals, Inc., certify that:
1. have reviewed this annual report on Form 10-K of Provectus
Pharmaceuticals, Inc.;
2. Based
on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state
a material fact necessary to make
the statements made, in light of the circumstances under which such
statements were
made, not misleading with respect to
the period covered by this report;
3. Based
on
my knowledge, the financial statements, and other financial
information included in this report, fairly present in
all material respects the
financial condition, results of operations and cash flows
of the smaller reporting company as of, and for, the
periods presented in this report;
4. The small business issuer's other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the smaller reporting company
and have:
a) Designed such disclosure controls and procedures, or
caused such
disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the smaller
reporting company, including
its consolidated subsidiaries, is made known to
us by others within those entities, particularly during
the period in which this report is being prepared;
b) Designed
such internal control
over financial reporting, or caused such
internal control over financial reporting to be
designed under
our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and
the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) Evaluated
the effectiveness of the smaller reporting company's disclosure
controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of
the period covered by this report based on such
evaluation;
d) Disclosed in
this report any change in the smaller reporting company 's
internal control over financial reporting that
occurred during the smaller reporting company's most recent fiscal
quarter that has materially affected, or
is reasonably likely to
materially affect, the smaller reporting company's
internal control over financial reporting; and
5. The
smaller reporting company's other certifying officers and I have disclosed,
based on our most recent evaluation of
internal control over financial reporting, to
the smaller reporting company's auditors and the audit committee of the smaller
reporting company 's board of directors (or
persons performing the equivalent functions):
a) All
significant deficiencies and material weaknesses in the design or
operation of
internal control over financial reporting which
are reasonably likely to adversely affect the
smaller reporting company's ability to record,
process, summarize and report financial information;
and
b) Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the smaller reporting company’s internal control over
financial reporting.
Date:
March 31, 2010
|
By:
|
/s/ H. Craig Dees | |
H. Craig Dees | |||
Chief Executive Officer | |||